决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Improved Efficacy of Triple-Negative Breast Cancer Immunotherapy via Hydrogel-Based Co-Delivery of CAR-T Cells and Mitophagy Agonist.
渗漏且结构异常的血管以及肿瘤间质内压力升高,会减少 CAR-T 细胞在包括三阴性乳腺癌(TNBC)在内的实体瘤中的浸润。
渗漏且结构异常的血管以及肿瘤间质内压力升高,会减少 CAR-T 细胞在实体瘤中的浸润,包括三阴性乳腺癌(TNBC)。此外,高肿瘤细胞负荷可能导致浸润的 CAR-T 细胞减少及其功能耗竭。在本研究中,建立了多种效应细胞与靶细胞(E:T)比例实验,以模拟使用 CAR-T 细胞治疗白血病(高 E:T 比例)和实体瘤(低 E:T 比例)。结果发现,在低 E:T 比例的实体瘤中,抗肿瘤免疫反应降低。此外,进行单细胞测序以研究低比例下的功能耗竭。结果揭示,抑制线粒体自噬介导的线粒体功能障碍削弱了 CAR-T 细胞疗法的抗肿瘤疗效。通过 AI 深度学习和细胞因子检测筛选出线粒体自噬激动剂 BC1618,体内和体外研究显示,BC1618 通过改善线粒体自噬显著增强了 CAR-T 细胞的抗肿瘤反应。在此,构建了可注射水凝胶,用于 CAR-T 细胞和 BC1618 的受控共递送,从而改善 TNBC 的治疗。水凝胶的局部递送在肿瘤部位形成炎症性和线粒体自噬增强的微环境,刺激 CAR-T 细胞增殖,持续提供抗肿瘤能力,并改善治疗效果。
Leaky and structurally abnormal blood vessels and increased pressure in the tumor interstitium reduce the infiltration of CAR-T cells in solid tumors, including triple-negative breast cancer (TNBC). Furthermore, high burden of tumor cells may cause reduction of infiltrating CAR-T cells and their functional exhaustion. In this study, various effector-to-target (E:T) ratio experiments are established to model the treatment using CAR-T cells in leukemia (high E:T ratio) and solid tumor (low E:T ratio). It is found that the antitumor immune response is decreased in solid tumors with low E:T ratio. Furthermore, single cell sequencing is performed to investigate the functional exhaustion at a low ratio. It is revealed that the inhibition of mitophagy-mediated mitochondrial dysfunction diminished the antitumor efficacy of CAR-T-cell therapy. The mitophagy agonist BC1618 is screened via AI-deep learning and cytokine detection, in vivo and in vitro studies revealed that BC1618 significantly strengthened the antitumor response of CAR-T cells via improving mitophagy. Here, injection hydrogels are engineered for the controlled co-delivery of CAR-T cells and BC1618 that improves the treatment of TNBC. Local delivery of hydrogels creates an inflammatory and mitophagy-enhanced microenvironment at the tumor site, which stimulates the CAR-T cells proliferation, provides antitumor ability persistently, and improves the effect of treatment.
MEMBER ACCOUNT
登录成功会直接打开下一页。